Wholesale distributors, organised pharmacy chains and e-pharmacies that move medicines from the plant to the patient.
MedPlus Health ServicesOperator · HighListed
Apollo Hospitals EnterpriseOperator · MediumListed
Entero Healthcare SolutionsOperator · HighListed
PharmEasy (API Holdings)Operator · HighUnlisted
Tata 1mgOperator · HighUnlisted
Apollo Hospitals Enterprise (APOLLOHOSP)
Hospital group whose Apollo HealthCo arm runs India's largest pharmacy chain (7,000+ stores), Apollo 24/7 and, via Keimed, wholesale pharma distribution
Price
₹8,448
snapshot 30 Oct 2026
Strengths
Largest organised pharmacy network and wholesale arm (Keimed) give real scale in drug distribution
Pharmacy and digital business is being demerged into Apollo Healthtech for a separate listing (targeted Q4 FY27)
Risks
Pharmacy is a minority of value inside a hospital-led group until the demerger completes
Apollo 24/7 digital losses and demerger execution risk
Note: Group figures are mostly hospitals; pharmacy/distribution sits in Apollo HealthCo
Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Moves finished medicines from manufacturers' C&F agents through stockists and distributors to roughly 12 lakh retail chemists, hospital pharmacies and e-pharmacies. Trade margins are capped by regulation (typically ~10% for wholesalers and ~20% for retailers on scheduled drugs).
Why it matters
India's medicine distribution is still highly fragmented. Organised chains (Apollo Pharmacy, MedPlus) and consolidators (Entero, Keimed) are taking share by offering reliable supply, private-label generics and digital ordering - a scale game with thin margins but large revenue and real network effects.
Where the value pool sits
High-volume, low-margin: distributors earn ~3-5% EBITDA and chains ~5-9%, so profitability depends on store maturity, private-label mix and working capital. Private-label generics can earn several times the margin of branded resale, which is why every chain pushes them.
Key drivers
Shift from unorganised chemists to chains and digital channels
Private-label generics and diagnostics/teleconsult bundling
Consolidation of fragmented regional distributors
Rising out-of-pocket health spend and insurance coverage
Potential bottlenecks
Regulated trade margins limit pricing
Working-capital intensity (inventory and stockist credit)
Unregulated e-pharmacy rules and pushback from chemist associations (AIOCD)